Abstract
Our Experience with Ranibizumab Biosimilar Results of OCEVA Multicentre Study Group : Chaitra Jayadev
1. Role of anti-VEGF in the management of inflammatory new vessels in uveitis – Dr Padmamalini M
2. Innovators vs Biosimilars – Dr Pradeep Kumar
3. Anti VEGFs in management of PDR – Dr Gopal Pillai
4. Multicenter experience with Oceva- Dr. Chaitra Jayadev
5. Panel discussion – chairs and speakers
| 1 | Role of anti-VEGF in the management of inflammatory new vessels in uveitis | Dr.Padmamalini Mahendradas | |
| 2 | Innovators vs Biosimilars | Prof. Dr.Pradeep Kumar | |
| 3 | Anti VEGFs in management of PDR | Prof.Gopal S. Pillai | |
| 4 | Multicenter experience with Oceva | Dr.Chaitra Jayadev |
